ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 23,800 shares, an increase of 33.0% from the September 15th total of 17,900 shares. Based on an average daily trading volume, of 95,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 2.2% of the company’s shares are sold short.

ZyVersa Therapeutics Stock Performance

ZyVersa Therapeutics stock opened at $2.32 on Friday. ZyVersa Therapeutics has a 52-week low of $2.08 and a 52-week high of $48.69. The firm has a 50 day moving average price of $2.64 and a two-hundred day moving average price of $4.21.

ZyVersa Therapeutics (NASDAQ:ZVSA) last released its quarterly earnings results on Friday, August 9th. The company reported ($3.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.20) by $1.89. Equities analysts expect that ZyVersa Therapeutics will post -22.7 earnings per share for the current fiscal year.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.